Veenat 400 mg – Composition, Uses and Medicine Enquiries
Product Overview
Veenat 400 mg contains Imatinib, a targeted anticancer medicine belonging to the tyrosine kinase inhibitor category. It works by blocking specific tyrosine kinase signals involved in abnormal cell growth and multiplication.
Imatinib may be prescribed for eligible patients with selected forms of chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST) and other specific conditions supported by the approved product label.
Treatment selection depends on the exact cancer diagnosis, diagnostic and molecular testing, previous treatment and the patient’s overall medical condition. The medicine is taken orally under the supervision of a qualified oncology specialist.
Treatment with Veenat requires appropriate clinical monitoring, which may include regular blood tests and assessment for possible adverse effects. Patients should not change their prescribed dose or discontinue treatment without discussing it with their cancer-care team.
Composition and Strength
The supplied product information identifies the following composition:
| Active Ingredient | Strength |
|---|---|
| Imatinib | 400 mg |
Product Name: Veenat 400 mg
Generic Name: Imatinib
Brand Name: Veenat
Strength: 400 mg
Please verify the exact formulation, dosage form and manufacturer details against the original product packaging before proceeding with an enquiry.
Therapeutic Category and Indication
Veenat 400 mg belongs to the anticancer medicine category and is classified as a tyrosine kinase inhibitor (TKI).
Its clinical use relates to selected cases of:
- Chronic myeloid leukemia (CML).
- Gastrointestinal stromal tumors (GIST).
- Other specific conditions where supported by the approved product information.
Imatinib blocks certain tyrosine kinase signals that contribute to abnormal cell growth. Its use depends on the specific cancer diagnosis and relevant diagnostic and molecular findings rather than symptoms alone.
The medicine is not appropriate for every patient with these conditions. Treatment decisions depend on diagnostic results, patient-specific factors, coexisting conditions, possible medicine interactions and applicable prescribing guidelines.
The indications listed here are a general overview, not a substitute for a prescriber’s assessment. The exact approved uses, restrictions and treatment protocols should be checked against the current local prescribing information.
Administration Information
Veenat 400 mg should be taken orally according to the instructions provided by the treating oncologist and the verified product information.
The supplied product information states that it should be taken with food and water. Patients should follow the specific instructions provided by their healthcare professional and swallow the medicine as directed.
The appropriate strength, schedule and treatment duration must be determined by the treating oncologist. Regular blood tests and other recommended monitoring should be attended as advised.
Patients should not independently adjust the dose, interrupt treatment or substitute medicines without consulting their cancer-care team. The prescribed schedule, duration and missed-dose instructions must be provided by the treating clinician.
Product Presentation and Availability
The product enquiry can be made using the following details:
- Product Name: Veenat 400 mg
- Generic Name: Imatinib
- Brand Name: Veenat
- Strength: 400 mg
- Therapeutic Category: Anticancer
- Medicine Class: Tyrosine Kinase Inhibitor
- Indications: Selected chronic myeloid leukemia and gastrointestinal stromal tumors.
The dosage form, company name, manufacturer, pack size and actual product presentation must be confirmed against the manufacturer’s labelled packaging.
Available packaging, batch identification, expiry date and remaining shelf life may vary and should be confirmed by an authorised supplier before any transaction.
A product listing does not confirm current stock, price, availability or eligibility for supply to a particular destination.
Prescription and Patient Safety
Veenat 400 mg is a prescription anticancer medicine and must be used under the supervision of an appropriately qualified oncology specialist.
Treatment requires individual clinical assessment and regular monitoring. Depending on the patient’s condition and treatment plan, monitoring may include blood counts and assessment for fluid retention, liver-related effects and other possible adverse reactions.
Patients should inform their healthcare professional about their medical history and all other medicines they are taking so that potential interactions and treatment-related risks can be evaluated.
The appropriate strength, schedule, duration and monitoring requirements must be determined by the treating oncologist. Patients should not start, interrupt, change or discontinue treatment based solely on website information.
The exact precautions, approved indications and possible adverse effects should be checked against the current approved product information.
Medicine Enquiry Coordination Through Medinglobal
Medinglobal provides medicine information, product identification and enquiry coordination. Where appropriate, Medinglobal may help patients, caregivers and eligible healthcare organisations communicate with independent, appropriately authorised pharmaceutical suppliers or service providers.
Medinglobal does not manufacture, stock, sell, dispense or prescribe Veenat through the website. Any regulated pharmaceutical activity, including prescription verification and lawful supply, remains the responsibility of the relevant independent provider and is subject to applicable laws and regulations.
Availability, prescription requirements, lawful supply routes, supporting documents and destination-country restrictions must be confirmed before any transaction. Submitting an enquiry does not guarantee supply or availability.
How to Submit a Veenat 400 mg Enquiry
To help identify the requested product, include the following details when submitting an enquiry:
- Product or brand name: Veenat 400 mg.
- Generic name: Imatinib.
- Required strength and dosage form.
- Required quantity.
- Destination country.
- Prescription or supporting documentation, where applicable.
Medinglobal may review the submitted details for identification and coordination purposes and, where appropriate, refer the enquiry to an authorised independent provider. The provider is responsible for its own verification, regulatory checks and any subsequent supply decision.
Frequently Asked Questions
What is Veenat 400 mg used for?
Veenat 400 mg contains Imatinib and is associated with the treatment of selected chronic myeloid leukemia and gastrointestinal stromal tumors. Eligibility and approved indications depend on the specific product label and the treating oncologist’s assessment.
What is the generic name of Veenat 400 mg?
The generic name is Imatinib.
What is the strength of Veenat listed on this page?
The supplied product information identifies Imatinib 400 mg. The exact formulation should be verified against the original product packaging.
What type of medicine is Veenat 400 mg?
Veenat belongs to the anticancer medicine category and is classified as a tyrosine kinase inhibitor.
Does Veenat 400 mg require medical supervision?
Yes. It is a prescription anticancer medicine that requires oncology supervision and appropriate clinical monitoring.
Can the dose be changed without medical advice?
No. Patients should not independently adjust the dose or stop treatment without consulting their treating oncologist.
Can international patients submit a Veenat enquiry through Medinglobal?
International enquiries may be submitted. Any coordination or subsequent supply depends on confirmation by an authorised independent provider and compliance with applicable regulations in the relevant countries.
Does Medinglobal sell or dispense Veenat directly?
No. Medinglobal provides product information, identification and enquiry coordination. It does not itself manufacture, sell, dispense or prescribe the medicine through the website.
Reviews
There are no reviews yet.